Standard BioTools Inc. Variable Lease, Cost
Standard BioTools Inc. (LAB) reported Variable Lease, Cost of $4.21 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-03-16
- Standard BioTools Inc. variable lease, cost for the quarter ending 2024-12-31 was $281.00K, a 62.38% decline year-over-year.
- Standard BioTools Inc. variable lease, cost for the quarter ending 2024-09-30 was $1.19M, a 43.13% increase year-over-year.
- Standard BioTools Inc. variable lease, cost for the quarter ending 2024-06-30 was $1.40M, a 70.07% increase year-over-year.
- Standard BioTools Inc. variable lease, cost for the quarter ending 2024-03-31 was $1.20M, a 56.21% increase year-over-year.
- Standard BioTools Inc. variable lease, cost for fiscal 2025 was $4.21M, a 3.59% increase from fiscal 2024.
- Standard BioTools Inc. variable lease, cost for fiscal 2024 was $4.06M, a 28.38% increase from fiscal 2023.
- Standard BioTools Inc. variable lease, cost for fiscal 2023 was $3.16M, a 7.99% increase from fiscal 2022.
- Standard BioTools Inc. variable lease, cost for fiscal 2022 was $2.93M, a 2.70% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month | Variable Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $4.21M 10-K · filed 2026-03-16 | ||||
| 2024-12-31 | $281.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.47M derived: sum of 2 quarters · filed 2026-03-16 | $2.87M derived: sum of 3 quarters · filed 2026-03-16 | $4.06M 10-K · filed 2026-03-16 | $5.00M 10-K · filed 2025-03-11 |
| 2024-09-30 | $1.19M 10-Q · filed 2024-11-06 | $2.59M derived: sum of 2 quarters · filed 2024-11-06 | $3.78M 10-Q · filed 2024-11-06 | $4.53M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-06-30 | $1.40M 10-Q · filed 2024-08-06 | $2.59M 10-Q · filed 2024-08-06 | $3.34M derived: sum of 3 quarters · filed 2026-03-16 | $4.17M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-03-31 | $1.20M 10-Q · filed 2024-05-09 | $1.94M derived: sum of 2 quarters · filed 2026-03-16 | $2.77M derived: sum of 3 quarters · filed 2026-03-16 | $3.59M derived: sum of 4 quarters · filed 2026-03-16 | |
| 2023-12-31 | $747.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.58M derived: sum of 2 quarters · filed 2026-03-16 | $2.40M derived: sum of 3 quarters · filed 2026-03-16 | $3.16M 10-K · filed 2026-03-16 | |
| 2023-09-30 | $830.00K 10-Q · filed 2024-11-06 | $1.65M derived: sum of 2 quarters · filed 2024-11-06 | $2.42M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $822.00K 10-Q · filed 2024-08-06 | $1.59M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $765.00K 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | $2.93M 10-K · filed 2025-03-11 | ||||
| 2021-12-31 | $2.85M 10-K · filed 2023-03-14 | ||||
| 2020-12-31 | $760.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $1.17M derived: sum of 2 quarters · filed 2022-03-08 | $1.72M derived: sum of 3 quarters · filed 2022-03-08 | $2.34M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $407.00K 10-Q · filed 2020-11-09 | $955.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.58M 10-Q · filed 2020-11-09 | $2.15M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-06-30 | $548.00K 10-Q · filed 2020-08-07 | $1.17M 10-Q · filed 2020-08-07 | $1.74M derived: sum of 3 quarters · filed 2021-02-25 | $2.49M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2020-03-31 | $621.00K 10-Q · filed 2020-05-11 | $1.19M derived: sum of 2 quarters · filed 2021-02-25 | $1.94M derived: sum of 3 quarters · filed 2021-02-25 | $2.65M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-12-31 | $573.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $1.32M derived: sum of 2 quarters · filed 2021-02-25 | $2.02M derived: sum of 3 quarters · filed 2021-02-25 | $2.62M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $748.00K 10-Q · filed 2020-11-09 | $1.45M derived: sum of 2 quarters · filed 2020-11-09 | $2.05M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $703.00K 10-Q · filed 2020-08-07 | $1.30M 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | $600.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |